Pharma Pulse 5/3/24: Wegovy Sales More Than Double, The Effects of the IRA & more

A Look at the Effects of the Inflation Reduction Act

Study explores how the Inflation Reduction Act’s Drug Price Negotiation Program and its maximum fair prices impact incentives for investments in post-approval activity.

Make Your Bed, Other Advice From Keynote Speaker William McRaven | 2024 Asembia

There was no mention of specialty pharmacy, value-based care, drug spend or GLP-1s. And healthcare came up only as the backdrop to some of his many stories, honed to deliver a pearl of wisdom. But William McRaven held the attention of the thousands in the audience at the Tuesday morning general session of the annual Asembia specialty pharmacy meeting, and he received a brief standing ovation.

Wegovy Sales More Than Double as Demand Soars

Sales of blockbuster obesity treatment Wegovy more than doubled in the first quarter as its manufacturer races to make more of the drug to meet surging demand.

Thermo Fisher Scientific Launches New CXCL10 Testing Service

For organ transplant recipients, life post-transplant involves a delicate balance between invasive monitoring and immunosuppression to reduce the risk of rejection, both of which may carry complications. Now, a simple, urine-based assay that detects the CXCL10 chemokine may make care more convenient and less invasive for the nearly 250,000 Americans living with a kidney transplant.

Model N on LinkedIn:

In this Pharmaceutical Executive interview, Jesse Mendelsohn discusses the trends in revenue management, including the value of data and analytics. Watch his video interview to learn more. 📽️ 👇

#RevenueOptimization #RevenueManagement #LifeSciences #ModelN

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs